Permanent deocclusion of a subset of occluded genes in 129TF × R1A (clone1) by AdC but not TSA treatment. (A) AdC treatment caused a permanent increase in the expression of occluded 129TF genes in 129TF × R1A (clone1). Expression level is measured as the aggregate expression of occluded 129TF genes scaled to that of their R1A orthologs. (B) Histogram of occluded 129TF genes based on their expression levels in AdC-treated sample. Expression levels of individual 129TF genes are scaled to that of their R1A orthologs, and divided into 100 bins (expression levels >1 were combined into the last bin). Only genes for which the R1A copies are expressed at ≥2 TPG are considered. (C) Activation of occluded 129TF genes in 129TF × R1A (clone1) by AdC treatment is permanent. Expression levels of occluded 129TF genes in AdC-recovered sample are tightly correlated to that in AdC-treated sample, indicating that occluded 129TF genes activated by AdC treatment remained similarly active after seven days of recovery without the drug. Expression level is measured in TPG; logarithmic scales are used to allow better visualization of expression levels. (D) TSA treatment caused a transient increase in the expression of occluded 129TF genes in 129TF × R1A (clone1). Expression level is measured in the same way as in A. (E) Histogram of occluded 129TF genes based on their expression levels in TSA-treated sample. Expression level is measured in the same way as in B. (F) Activation of occluded 129TF genes in 129TF × R1A (clone1) by TSA treatment is transient. Activation of occluded 129TF genes in 129TF × R1A (clone1) by TSA treatment is reversed in TSA-recovered (1d) sample, indicating the highly transient nature of the activation. Expression level is measured in TPG.
